Option Care Health, Inc. $OPCH Shares Sold by Gamco Investors INC. ET AL

Key Points

• Gamco Investors INC. ET AL has reduced its stake in Option Care Health, Inc. by 15.9%, selling 17,302 shares and now owning 91,655 shares valued at approximately $3.2 million.
• Directors Timothy P. Sullivan and Harry M. Jansen Kraemer, Jr. made significant stock purchases of 20,000 and 36,000 shares respectively, reflecting insider confidence in the company's prospects.
• Option Care Health reported a 15.4% increase in revenue year-over-year, achieving $1.42 billion for the quarter, exceeding analyst expectations.

Gamco Investors INC. ET AL lowered its position in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 15.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 91,655 shares of the company's stock after selling 17,302 shares during the quarter. Gamco Investors INC. ET AL owned about 0.06% of Option Care Health worth $3,203,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Compass Wealth Management LLC boosted its stake in shares of Option Care Health by 8.9% during the first quarter. Compass Wealth Management LLC now owns 166,078 shares of the company's stock valued at $5,804,000 after purchasing an additional 13,600 shares in the last quarter. Bessemer Group Inc. lifted its holdings in Option Care Health by 62.3% during the first quarter. Bessemer Group Inc. now owns 1,560 shares of the company's stock worth $54,000 after buying an additional 599 shares during the period. Principal Financial Group Inc. boosted its position in Option Care Health by 1.4% during the 1st quarter. Principal Financial Group Inc. now owns 485,871 shares of the company's stock valued at $16,981,000 after acquiring an additional 6,616 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Option Care Health by 25.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 8,274 shares of the company's stock valued at $289,000 after acquiring an additional 1,691 shares during the period. Finally, GAMMA Investing LLC raised its position in shares of Option Care Health by 307.1% in the 1st quarter. GAMMA Investing LLC now owns 3,192 shares of the company's stock worth $112,000 after acquiring an additional 2,408 shares in the last quarter. Hedge funds and other institutional investors own 98.05% of the company's stock.

Insider Transactions at Option Care Health

In other news, Director Harry M. Jansen Kraemer, Jr. purchased 36,000 shares of the company's stock in a transaction dated Wednesday, August 20th. The stock was acquired at an average price of $27.15 per share, with a total value of $977,400.00. Following the purchase, the director directly owned 375,390 shares in the company, valued at approximately $10,191,838.50. This represents a 10.61% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Timothy P. Sullivan acquired 20,000 shares of the stock in a transaction that occurred on Thursday, August 21st. The stock was acquired at an average price of $27.51 per share, with a total value of $550,200.00. Following the completion of the transaction, the director directly owned 49,229 shares of the company's stock, valued at $1,354,289.79. This trade represents a 68.43% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.64% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. JMP Securities boosted their target price on shares of Option Care Health from $36.00 to $38.00 and gave the stock a "market outperform" rating in a report on Thursday, July 31st. Barrington Research restated an "outperform" rating and issued a $38.00 target price on shares of Option Care Health in a research note on Thursday, July 10th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Option Care Health in a research report on Thursday, July 31st. Eight research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $35.75.

Option Care Health Stock Performance

Shares of NASDAQ OPCH traded down $0.32 during trading on Tuesday, reaching $28.36. 1,291,928 shares of the company traded hands, compared to its average volume of 1,855,288. The stock has a market cap of $4.60 billion, a P/E ratio of 22.69, a PEG ratio of 1.75 and a beta of 0.83. The firm's fifty day simple moving average is $29.55 and its 200 day simple moving average is $31.63. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.81. Option Care Health, Inc. has a 12-month low of $21.39 and a 12-month high of $35.53.

Option Care Health (NASDAQ:OPCH - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.40 by $0.01. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%.The company had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.35 billion. During the same period last year, the company earned $0.30 earnings per share. Option Care Health's quarterly revenue was up 15.4% compared to the same quarter last year. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, research analysts anticipate that Option Care Health, Inc. will post 1.22 earnings per share for the current fiscal year.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.